UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experience

Melotti, Dario; Asher, Samir; Troy-Barnes, Ethan; Nesr, George; Wilson, William; Camilleri, Marquita; Popat, Rakesh; ... Kyriakou, Chara; + view all (2024) Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experience. eJHaem , 5 (5) 10.1002/jha2.977. Green open access

[thumbnail of eJHaem - 2024 - Melotti - Outcomes of melphalan 140 mg m2 followed by autologous stem cell transplantation in multiple.pdf]
Preview
Text
eJHaem - 2024 - Melotti - Outcomes of melphalan 140 mg m2 followed by autologous stem cell transplantation in multiple.pdf - Published Version

Download (393kB) | Preview

Abstract

High-dose melphalan followed by stem cell rescue is the standard consolidative therapy for transplant-eligible patients with multiple myeloma (MM) in the United Kingdom. A melphalan dose of 200 mg/m2 (Mel200) is considered the "gold standard" for autologous stem cell transplant (ASCT) conditioning for fit patients ≤70 years old; however, with a peak diagnosis incidence at 80-89 years old in the UK dose adjustments will be inevitable to limit toxicities. In this single-centre UK-based retrospective analysis, data was collected from patients with plasma cell dyscrasias who underwent a first reduced-intensity, Mel140, ASCT from 2006 to 2019, a total of 81 patients. We found that the procedure was overall safe with seven (9%) of patients requiring ITU admission and a single transplant-related death within the initial autograft admission. The progression-free survival (PFS) and overall survival were comparable with those previously reported in the literature with median PFS for our cohort of 31 months. Univariate analysis of our data showed an inferior PFS for patients aged ≥70 years. In conclusion, although this is a retrospective analysis, it demonstrates that dose-reduced melphalan conditioning is safe and effective in patients deemed unfit for standard-intensity conditioning.

Type: Article
Title: Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experience
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/jha2.977
Publisher version: https://doi.org/10.1002/jha2.977
Language: English
Additional information: © 2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: Haematology, multiple myeloma, transplantation
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10200449
Downloads since deposit
90Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item